Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 539,928
  • Shares Outstanding, K 54,815
  • Annual Sales, $ 95,390 K
  • Annual Income, $ -368,010 K
  • 60-Month Beta 3.13
  • Price/Sales 3.92
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.67
  • Number of Estimates 4
  • High Estimate -1.48
  • Low Estimate -1.83
  • Prior Year -1.88
  • Growth Rate Est. (year over year) +11.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.11 +21.46%
on 01/08/20
12.58 -21.70%
on 12/18/19
-2.32 (-19.06%)
since 12/17/19
3-Month
2.93 +236.18%
on 10/28/19
17.37 -43.29%
on 12/02/19
+6.19 (+169.13%)
since 10/17/19
52-Week
2.93 +236.18%
on 10/28/19
32.05 -69.27%
on 02/28/19
-12.52 (-55.97%)
since 01/17/19

Most Recent Stories

More News
Biotech Sector's Technological Advancements Winning Major Battles in the War on Cancer

USA News Group - In the war against cancer, it appears that all hands are on deck, with contributions coming from across the biotech sector. As the 2020s begin, new approvals and promising data are encouraging...

ONCY : 3.10 (-2.52%)
ONC.TO : 4.05 (-2.41%)
GSK : 47.89 (+1.55%)
MRK : 90.97 (-0.23%)
CLVS : 9.85 (+3.96%)
AEMD : 2.06 (-25.36%)
Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review

Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.

MRK : 90.97 (-0.23%)
GSK : 47.89 (+1.55%)
AZN : 51.33 (+1.62%)
CLVS : 9.85 (+3.96%)
Watch for Clovis Oncology to Potentially Pullback After Gaining 14.94% Yesterday

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $10.00 to a high of $11.18. Yesterday, the shares gained 14.9%, which took the trading range above the 3-day high...

CLVS : 9.85 (+3.96%)
Clovis Oncology's Rubraca(R) (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer

--- FDA submission based on data from TRITON clinical program in advanced prostate cancer

CLVS : 9.85 (+3.96%)
Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020

Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020

PRTK : 3.64 (-4.21%)
GGB : 5.14 (+2.19%)
CPE : 3.86 (-5.85%)
CLVS : 9.85 (+3.96%)
AM : 7.24 (-4.36%)
Clovis Oncology Announces Debt Refinancing Transaction

Clovis Oncology, Inc. (NASDAQ: CLVS) (the "Company") announced today that on January 6, 2020 it priced a registered direct offering (the "Share Offering") of an aggregate of 17,777,679 shares (the "Shares")...

JPM : 138.20 (+0.69%)
CLVS : 9.85 (+3.96%)
Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019

--Q4/FY2019 Operating Results call planned for February 24, 2020

CLVS : 9.85 (+3.96%)
Implied Volatility Surging for Clovis (CLVS) Stock Options

Investors need to pay close attention to Clovis (CLVS) stock based on the movements in the options market lately.

CLVS : 9.85 (+3.96%)
Clovis Oncology has the Best Relative Performance in the Biotechnology Industry (CLVS , EPZM , SGMO , NVTA , FOLD )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

CLVS : 9.85 (+3.96%)
EPZM : 26.72 (+4.62%)
SGMO : 8.37 (-5.37%)
FDA Accepts Immunomedics' BLA Refiling for Breast Cancer Drug

The FDA accepts Immunomedics' (IMMU) BLA resubmission for sacituzumab govitecan to treat patients with metastatic triple-negative breast cancer, having received at least two prior therapies.

RHHBY : 42.4200 (+1.60%)
AZN : 51.33 (+1.62%)
IMMU : 19.00 (-1.78%)
CLVS : 9.85 (+3.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade CLVS with:

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

2nd Resistance Point 10.63
1st Resistance Point 10.24
Last Price 9.85
1st Support Level 9.41
2nd Support Level 8.97

See More

52-Week High 32.05
Fibonacci 61.8% 20.93
Fibonacci 50% 17.49
Fibonacci 38.2% 14.05
Last Price 9.85
52-Week Low 2.93

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar